iRhythm Technologies, Inc. (IRTC)
NASDAQ: IRTC · Real-Time Price · USD
154.71
+2.02 (1.32%)
At close: Jun 27, 2025, 4:00 PM
160.00
+5.29 (3.42%)
After-hours: Jun 27, 2025, 7:03 PM EDT
iRhythm Technologies Revenue
iRhythm Technologies had revenue of $158.68M in the quarter ending March 31, 2025, with 20.27% growth. This brings the company's revenue in the last twelve months to $618.59M, up 20.54% year-over-year. In the year 2024, iRhythm Technologies had annual revenue of $591.84M with 20.13% growth.
Revenue (ttm)
$618.59M
Revenue Growth
+20.54%
P/S Ratio
7.37
Revenue / Employee
$309,294
Employees
2,000
Market Cap
4.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 591.84M | 99.16M | 20.13% |
| Dec 31, 2023 | 492.68M | 81.76M | 19.90% |
| Dec 31, 2022 | 410.92M | 88.10M | 27.29% |
| Dec 31, 2021 | 322.83M | 57.66M | 21.74% |
| Dec 31, 2020 | 265.17M | 50.61M | 23.59% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IRTC News
- 13 hours ago - IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC - Business Wire
- 4 days ago - New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease - GlobeNewsWire
- 10 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Stockholders to Inquire about Securities Investigation - Accesswire
- 12 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation - Accesswire
- 15 days ago - iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 17 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect - Accesswire
- 19 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect - Accesswire
- 22 days ago - iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire